Polysaccharide Nanocomposite Hydrogel Prevents the Polarity Reversal of β-Glucan-Activated Macrophages by Lactate Oxidase-Based Lactate Depletion for Enhanced Immunotherapy
ACS Applied Materials & Interfaces · 19.08.2026 · 18 (32) · 44351-44366
DOI: 10.1021/acsami.6c04050 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 07.08.2026. Verfasst von Lu Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University,…. Hauptthemen laut MEDLINE: beta-Glucans, Hydrogels, Immunotherapy, Nanocomposites. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Science and Technology Research Program of Chongqing Municipal Education Commission.
Abstract (Originalsprache)
Modulating the immunosuppressive tumor microenvironment (TME) represents a promising strategy for improving cancer immunotherapy. A key approach involves reprogramming tumor-associated macrophages (TAMs) from a protumorigenic M2 phenotype to an antitumorigenic M1 state. However, elevated lactate concentration in the TME not only sustains the M2 phenotype but also impairs therapeutic efficacy. To address this challenge, we developed an in situ injectable carboxymethyl chitosan/oxidized sodium alginate (CMCS/OSA) hydrogel with pH-responsive release properties, coloaded with another nanosized active polysaccharide β-glucan and a lactate-depleting agent lactate oxidase (LOX). Under the acidic conditions of the TME, Schiff base bonds within the hydrogel matrix dissociate, triggering the controlled release of β-glucan nanoparticles and LOX. The β-glucan nanoparticles specifically target TAMs via the dendritic cell-associated C-type lectin 1 (Dectin 1) receptor, facilitating their phenotypic conversion from M2 to M1. Simultaneously, the released LOX continuously degrades lactate, preventing the reversion of TAMs back to the M2 phenotype. Collectively, our results demonstrated that this nanocomposite polysaccharide hydrogel system effectively promoted and maintained TAM polarization toward the M1 phenotype through the synergistic effects of immune modulation and metabolic regulation, ultimately enhancing the efficacy of tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu610031, China.
- Pharmacy Department, People's Hospital of Kaizhou, Chongqing405400, China.
- College of Medicine, Southwest Jiaotong University , Chengdu610031, China.
- Chongqing Three Gorges Medical College , Chongqing404120, China.
ORCID-Profile: Yi Wang
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Science and Technology Research Program of Chongqing Municipal Education Commission
Zitieren
APA
Li, L., Liao, M., Feng, J., Ma, H., Sun, Y., Sun, P., Tan, X., & Wang, Y. (2026). Polysaccharide Nanocomposite Hydrogel Prevents the Polarity Reversal of β-Glucan-Activated Macrophages by Lactate Oxidase-Based Lactate Depletion for Enhanced Immunotherapy. ACS Applied Materials & Interfaces, 18(32), 44351-44366. https://doi.org/10.1021/acsami.6c04050
Vancouver
Li L, Liao M, Feng J, Ma H, Sun Y, Sun P, et al. Polysaccharide Nanocomposite Hydrogel Prevents the Polarity Reversal of β-Glucan-Activated Macrophages by Lactate Oxidase-Based Lactate Depletion for Enhanced Immunotherapy. ACS Applied Materials & Interfaces. 2026;18(32):44351-44366. doi:10.1021/acsami.6c04050
BibTeX
@article{Li2026,
author = {Li, Lu and Liao, Minghui and Feng, Jie and Ma, Hongxuan and Sun, Yu and Sun, Ping and Tan, Xiaoyan and Wang, Yi},
title = {Polysaccharide Nanocomposite Hydrogel Prevents the Polarity Reversal of β-Glucan-Activated Macrophages by Lactate Oxidase-Based Lactate Depletion for Enhanced Immunotherapy},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
volume = {18},
number = {32},
pages = {44351--44366},
doi = {10.1021/acsami.6c04050}
}
EUVIMED